Total Voting Rights Update

RNS Number : 5017Q

Shield Therapeutics PLC

26 February 2021

 

Shield Therapeutics plc

("Shield" or the "Group")

Total Voting Rights Update

London, UK, 26 February 2021:  Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer® (ferric maltol), confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of 118,544,379 ordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.

The above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Tim Watts, Chief Executive Officer	[phone]
Lucy Huntington-Bailey, General Counsel and Company Secretary	[phone]
Nominated Advisor and Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden	[phone]
Joint Broker finnCap Ltd  Geoff Nash/Matt Radley/Alice Lane	[phone]
Financial PR & IR Advisor
Walbrook PR	[phone] or  [e-mail]
Paul McManus/Lianne Cawthorne	[phone] / [phone]

About Shield Therapeutics plc

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol) ®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield is quoted on AIM (STX). For more information about Shield, please see www.shieldtherapeutics.com

 

END

 

 

TVRBQLFLFLLFBBX